Susan Tansey is Vice President and Global Head for Therapeutic Strategy having trained in pediatrics in the U.K.'s National Health Service specializing in respiratory pediatrics and neonatology. She joined industry in 1998 and has since worked in clinical development in several therapeutic areas including cardiovascular, vaccine research and oncology. She has developed a specific expertise in pediatric clinical trials and currently is Chair for a working party at the European Network for Paediatric Research at the EMA, and also chairs the Children's Research Industry Group for the National Institute for Health Research's Clinical Research Network.
Previously, Susan worked at Servier in their UK R&D department as Clinical Research Manager covering the cardiovascular therapeutic area, followed by more than six years heading up global vaccine trials for Wyeth/Pfizer where she was a member of the global submission team for Prevenar 13, providing medical leadership for studies in Europe, India, the US and China. She then joined TMC Pharma as Director of Medical Services for 18 months after which she moved to Premier Research as their Senior Director in Paediatrics.
Susan obtained her medical degree from Manchester University and also holds the MRCP (UK) qualification. She is a consultant Pharmaceutical Physician (CCST 2011), a member of the Royal College of Paediatrics and Child Health and a Fellow of the Faculty of Pharmaceutical Medicine. She was a member of the Nuffield Council of Bioethics Working Party on Children and Clinical Research that published their report in May 2015.